{"id":10398,"date":"2021-11-05T10:35:00","date_gmt":"2021-11-05T07:35:00","guid":{"rendered":"https:\/\/roboforex.com\/blog\/?p=10398"},"modified":"2023-06-22T17:43:36","modified_gmt":"2023-06-22T14:43:36","slug":"weak-forecast-dropped-moderna-shares","status":"publish","type":"post","link":"https:\/\/roboforex.com\/blog\/2021\/11\/05\/weak-forecast-dropped-moderna-shares\/","title":{"rendered":"Weak Forecast Dropped Moderna Shares"},"content":{"rendered":"\n

Right after Pfizer reported its financial performance in Q3<\/a>, 2021, another US pharma company – Moderna – presented its report.<\/p>\n\n\n\n

The manufacturer of messenger RNA-based drugs reported growth of revenue in July-September by over 3,000%, but then its shares started falling rapidly. Let’s get into the reasons of this decline together.<\/p>\n\n\n\n

<\/span><\/a>Moderna report for Q3: revenue grows by 3,065%<\/span><\/h2>\n\n\n\n

On November 4th, a biotech company called Moderna reported its performance in Q3 that ended on September 30th. Below you can see the exact digits, and many of you will call this a success. However, Wall Street analysts have a different viewpoint. They were genuinely discouraged, and I’ll explain this later.<\/p>\n\n\n\n

The main source of finance was sales of the anticoronavirus vaccine. In July-September, Moderna sold 208 million dozes. Sales of other drugs brought $4.81 billion, and the revenue from grants – just $140 million.<\/p>\n\n\n\n

<\/span><\/a>Important report details<\/span><\/h3>\n\n\n\n